Nexavar

Bombay HC in favor of Natco\’s Compulsory License

Leave a Comment / August 2014, Newsletter / By / , , , ,

Recently, Bombay High Court supported the Granted compulsory license to Indian pharma company Natco for the sale of a generic version of Bayer’s anti-cancer drug Nexavar. With this decision, Natco will now be legally able to manufacture and sell the generic copy of sorafenib tosylate, a patented kidney cancer drug invented by German Pharma giant …

Bombay HC in favor of Natco\’s Compulsory License Read More »

US and India sparring over IPR and trade practices

Leave a Comment / News Updates / By / , , , , ,

US and India have been sparring over IPR and trade practices. To begin with US claimed that India’s IPR regime discriminated against U.S. companies, especially in the pharmaceuticals sector, and had expressed concerns over issuing a compulsory license (CL), to Hyderabad-based Natco Pharma to manufacture and produce cancer drug Nexavar at a price 30 times …

US and India sparring over IPR and trade practices Read More »

What is your IP portfolio? ipMetrix provides value-added research and strategy for all IP classes.
  • No.84,1st Floor, 1st Main Road,
    Panduranga Nagar, Bannerghatta Road
    Bangalore - 560 076.
Linkedin-in

© 2024 ipMetrix. All Rights Reserved

Get A Quote
Get A Quote